Trial reportDrug design, development and therapy2025
Effects of Remimazolam Tosilate Combined with Esketamine on Anesthetic Efficacy and Psychiatric Symptoms in Patients Undergoing Ambulatory Surgery: A Randomized Controlled Study.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy and Safety of Esketamine-Lidocaine for Anesthesia Induction in Elderly Patients Undergoing Elective Surgery: A Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
- The median effective dose (EDBMC anesthesiology · 2026Article
- Progress in the Application of Esketamine During the Perioperative Period.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The choice of anesthetic drugs is crucial in ambulatory surgery. Esketamine has anesthetic, analgesic, and sedative effects, but it is associated with dose-dependent psychiatric symptoms. Benzodiazepines can alleviate these symptoms, but traditional drugs like midazolam may prolong the recovery time. Remimazolam tosilate as a novel benzodiazepine, has not been fully explored in terms of its effects when combined with esketamine and its impact on psychiatric symptoms. Methods: A total of 249 patients undergoing elective laparoscopic surgery were enrolled. Randomly divided into the esketamine group (Group E), the esketamine plus midazolam group (Group EM), and the esketamine plus remimazolam tosilate group (Group ER). The primary outcome was the incidence of adverse reactions. The secondary outcomes included hemodynamics at different time points: at rest in the room (T0), immediately post-intubation (T1), immediately post-extubation (T2), 30 minutes following extubation (T3), and immediately after leaving the PACU (T4). Moreover, we also documented the Riker Sedation-Agitation Scale (SAS) scores at T2-4, as well as extubation time and PACU stay duration. Results: Patients in Group ER had a significantly lower incidence of postoperative diplopia and blurry vision compared to Groups E and EM ( Conclusion: The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.